Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study

Bibliographic Details
Title: Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study
Authors: Antonio Muscatello, Silvia Nozza, Massimiliano Fabbiani, Ilaria De Benedetto, Marco Ripa, Raffaele Dell’Acqua, Andrea Antinori, Carmela Pinnetti, Andrea Calcagno, Micol Ferrara, Emanuele Focà, Eugenia Quiros-Roldan, Diego Ripamonti, Marco Campus, Benedetto Maurizio Celesia, Carlo Torti, Lucio Cosco, Antonio Di Biagio, Stefano Rusconi, Giulia Marchetti, Cristina Mussini, Roberto Gulminetti, Antonella Cingolani, Gabriella D’Ettorre, Giordano Madeddu, Antonina Franco, Giancarlo Orofino, Nicola Squillace, Andrea Gori, Giuseppe Tambussi, Alessandra Bandera
Source: Pathogens and Immunity, Vol 5, Iss 1, Pp 8-33 (2020)
Publisher Information: Case Western Reserve University, 2020.
Publication Year: 2020
Collection: LCC:Pathology
LCC:Immunologic diseases. Allergy
Subject Terms: acute/early hiv infection, early antiretroviral treatment, optimal immunological recovery, intensified antiretroviral regimen, Pathology, RB1-214, Immunologic diseases. Allergy, RC581-607
More Details: Background: Viral load peak and immune activation occur shortly after exposure during acute or early HIV infection (AEHI). We aimed to define the benefit of early start of antiretroviral treatment (ART) during AEHI in terms of immunological recovery, virological suppression, and treatment discontinuation. Setting: Patients diagnosed with AEHI (Fiebig stages I-V) during 2008-2014 from an analysis of 20 Italian centers. Methods: This was an observational, retrospective, and multicenter study. We investigated the effect of early ART (defined as initiation within 3 months from AEHI diagnosis) on time to virological suppression, optimal immunological recovery (defined as CD4 count ≥ 500/µL, CD4 ≥ 30%, and CD4/CD8 ≥ 1), and first-line ART regimen discontinuation by Cox regression analysis. Results: There were 321 patients with AEHI included in the study (82.9% in Fiebig stage III-V). At diagnosis, the median viral load was 5.67 log10copies/mL and the median CD4 count was 456 cells/µL. Overall, 70.6% of patients started early ART (median time from HIV diagnosis to ART initiation 12 days, IQR 6-27). Higher baseline viral load and AEHI diagnosis during 2012-2014 were independently associated with early ART. HBV co-infection, baseline CD4/CD8 ≥ 1, lower baseline HIV-RNA, and AEHI diagnosis in recent years (2012-2014) were independently associated with a shorter time to virological suppression. Early ART emerged as an independent predictor of optimal immunological recovery after adjustment for baseline CD4 (absolute and percentage count) and CD4/CD8 ratio. The only independent predictor of first-line ART discontinuation was an initial ART regimen including > 3 drugs. Conclusions: In a large cohort of well-characterized patients with AEHI, we confirmed the beneficial role of early ART on CD4+ T-cell recovery and on rates of CD4/CD8 ratio normalization. Moreover, we recognized baseline CD4/CD8 ratio as an independent factor influencing time to virological response in the setting of AEHI, thus giving new insights into research of immunological markers associated with virological control.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2469-2964
Relation: https://paijournal.com/index.php/paijournal/article/view/341; https://doaj.org/toc/2469-2964
DOI: 10.20411/pai.v5i1.341
Access URL: https://doaj.org/article/5a37128b58f04d51ba14e804b0f945aa
Accession Number: edsdoj.5a37128b58f04d51ba14e804b0f945aa
Database: Directory of Open Access Journals
More Details
ISSN:24692964
DOI:10.20411/pai.v5i1.341
Published in:Pathogens and Immunity
Language:English